{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:49:58Z","timestamp":1793933398799,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We analyzed the outcome of 2229 patients with myelofibrosis (MF) treated with ruxolitinib before and after the COVID-19 pandemic. Two populations of MF were defined from the AIFA web monitoring registries: the pre-COVID-19 (1703, 76.4%) and the post-COVID-19 (526, 23.6%) cohorts. The two populations were balanced using the Inversity Probability of Treatment Weighting. The median age was 69 years and 73 years in the pre- and post- COVID-19 era, respectively. There were no differences in spleen diameters at baseline prior to ruxolitinib in the two groups, but a difference in median spleen volume was noted (961 cm3 in the pre-era and 788.3 cm3 in the post-era). Overall, intermediate-2 IPSS risk were 67.2% in the pre- and 72% in the post-era, whereas the high-risk category was 32.7% and 27.9%, respectively. More patients started on a reduced dose in the post-COVID-19 era (73.5% versus 65% in the pre-era). After adjusting for the differences, an analysis of overall survival revealed no differences between the two groups (HR 0.875,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05). Patients who started ruxolitinib after COVID-19 had similar probability to stop treatment in the follow-up (HR 0.956,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05). The results indicate that COVID-19 did not affect the duration of treatment and the relative OS.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06601-w","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:35:10Z","timestamp":1758328510000},"page":"4577-4583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries"],"prefix":"10.1007","volume":"104","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Celant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Olimpieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Guarcello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Alberto","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"6601_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","volume":"63","author":"X Xu","year":"2020","unstructured":"Xu X, Chen P, Wang J, Feng J, Zhou H, Li X et al (2020) Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its Spike protein for risk of human transmission. Sci China Life Sci 63:457\u2013460","journal-title":"Sci China Life Sci"},{"key":"6601_CR2","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1097\/HS9.0000000000000609","volume":"5","author":"J Saunders","year":"2021","unstructured":"Saunders J, Curto-Garcia N, Sriskandarajah P, O\u2019Sullivan J, Woodley C, Asirvatham S et al (2021) Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021. HemaSphere 5:e609","journal-title":"HemaSphere"},{"key":"6601_CR3","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1038\/s41375-020-01032-0","volume":"34","author":"M Breccia","year":"2020","unstructured":"Breccia M, Piciocchi A, De Stefano V, Finazzi G, Iurlo A, Fazi P et al (2020) COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. Leukemia 34:2813\u20132814","journal-title":"Leukemia"},{"key":"6601_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","volume":"35","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A et al (2021) High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia 35:485\u2013493","journal-title":"Leukemia"},{"key":"6601_CR5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bjh.16956","volume":"190","author":"D El-Sharkawi","year":"2020","unstructured":"El-Sharkawi D, Iyengar S (2020) Haematological cancers and the risk of severe COVID-19: exploration and critical evaluation of the evidence to date. Br J Haematol 190:336\u2013345","journal-title":"Br J Haematol"},{"key":"6601_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41408-021-00509-0","volume":"11","author":"T Barbui","year":"2021","unstructured":"Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G et al (2021) Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J 11:115","journal-title":"Blood Cancer J"},{"key":"6601_CR7","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1038\/s41375-022-01675-1","volume":"36","author":"M Breccia","year":"2022","unstructured":"Breccia M, Piciocchi A, Messina M, Soddu S, De Stefano V, Bellini M et al (2022) Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine. Leukemia 36:2548\u20132550","journal-title":"Leukemia"},{"key":"6601_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","volume":"14","author":"F Pimpinelli","year":"2021","unstructured":"Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P et al (2021) Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol 14:81","journal-title":"J Hematol Oncol"},{"key":"6601_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107330","volume":"131","author":"A Atanasio","year":"2023","unstructured":"Atanasio A, Vanni A, Maggi L, Pilerci S, Mazzoni A, Capone M et al (2023) Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy. Leuk Res 131:107330","journal-title":"Leuk Res"},{"key":"6601_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1117815","volume":"13","author":"GA Palumbo","year":"2023","unstructured":"Palumbo GA, Cambria D, La Spina E, Duminuco A, Laneri A, Longo A et al (2023) Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. Front Oncol 13:1117815","journal-title":"Front Oncol"},{"key":"6601_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106819","volume":"116","author":"G Auteri","year":"2022","unstructured":"Auteri G, Bartoletti D, Di Pietro C, Sutto E, Mazzoni C, Romagnoli AD et al (2022) Longer-term response to SARS-CoV-2 vaccine in MPN patients: role of ruxolitinib and disease severity. Leuk Res 116:106819","journal-title":"Leuk Res"},{"key":"6601_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10:55","journal-title":"J Hematol Oncol"},{"key":"6601_CR13","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L et al (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30:1701\u20131707","journal-title":"Leukemia"},{"key":"6601_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01186","volume":"9","author":"EM Elli","year":"2019","unstructured":"Elli EM, Barat\u00e8 C, Mendicino F, Palandri F, Palumbo GA (2019) Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol 9:1186","journal-title":"Front Oncol"},{"key":"6601_CR15","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","volume":"8","author":"K Maneikis","year":"2021","unstructured":"Maneikis K, Sablauskas K, Ringeleviciut\u00e8 U, Vaitekenait\u00e8 V, Cekauskiene R, Kryzauskait\u00e8 L et al (2021) Immunogenicity of the BNT162B2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in lithuania: a National prospective cohort study. Lancet Haematol 8:e583\u2013e592","journal-title":"Lancet Haematol"},{"key":"6601_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00277-021-04406-1","volume":"100","author":"M Breccia","year":"2021","unstructured":"Breccia M, Celant S, Olimpieri PP et al (2021) Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second-generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian medicines agency (AIFA). Ann Hematol 100:481\u2013485","journal-title":"Ann Hematol"},{"key":"6601_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00277-023-05168-8","volume":"4","author":"M Breccia","year":"2023","unstructured":"Breccia M, Olimpieri PP, Celant S et al (2023) Effectiveness and management of Ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA). Ann Hematol 4:1257\u20131259","journal-title":"Ann Hematol"},{"key":"6601_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/sim.3782","volume":"29","author":"BK Lee","year":"2010","unstructured":"Lee BK, Lessler J, Stuart EA (2010) Improving propensity score weighting using machine learning. Stat Med 29:337\u2013346","journal-title":"Stat Med"},{"key":"6601_CR19","unstructured":"R Core Team. R: A language and environment for statistical computing (2021) ; R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/"},{"key":"6601_CR20","doi-asserted-by":"crossref","unstructured":"Lumley T (2010) Complex surveys: A guide to analysis using R. Wiley","DOI":"10.1002\/9780470580066"},{"key":"6601_CR21","unstructured":"Kassambara A, Kosinski M, Biecek P, Survminer Drawing Survival Curves using \u2018ggplot2. 2021; R package version 0.4.9. https:\/\/CRAN.R-project.org\/package=survminer"},{"key":"6601_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/sim.9681","volume":"42","author":"R Denz","year":"2023","unstructured":"Denz R, Klaa\u00dfen-Mielke R, Timmesfeld N (2023) A comparison of different methods to adjust survival curves for confounders. Stat Med 42:1461\u20131479","journal-title":"Stat Med"},{"key":"6601_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/bjh.19812","volume":"206","author":"M Breccia","year":"2025","unstructured":"Breccia M, Celant S, Palandri F et al (2025) The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: a prospective real-world study on AIFA monitoring registries. Br J Haematol 206:172\u2013179","journal-title":"Br J Haematol"},{"key":"6601_CR24","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/cncr.34707","volume":"129","author":"S Vesrtovsek","year":"2023","unstructured":"Vesrtovsek S, Kiladjian JJ, Vannucchi AM et al (2023) Early intervention in myelofibrosis and impact on outcomes: a pooled analysis of the COMFORT-I and COMFORT-II studies. Cancer 129:1681\u20131690","journal-title":"Cancer"},{"key":"6601_CR25","doi-asserted-by":"publisher","first-page":"750346","DOI":"10.3389\/fimmu.2021.750346","volume":"12","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, Iurlo A (2021) Immune dysregulation and infectious complications in MPN patients treated with JAK inhibitors. Front Immunol 12:750346","journal-title":"Front Immunol"},{"key":"6601_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.16174","volume":"187","author":"E Sant\u2019Antonio","year":"2019","unstructured":"Sant\u2019Antonio E, Bonifacio M, Breccia M, Rumi E (2019) A journey through infectious risk associated with ruxolitinib. Br J Haematol 187:286\u2013295","journal-title":"Br J Haematol"},{"key":"6601_CR27","unstructured":"Ash Research Collaborative. COVID-19 Registry (2021) Available online: https:\/\/www.ashresearchcollaborative.org\/s\/covid-19-registry"},{"key":"6601_CR28","doi-asserted-by":"publisher","unstructured":"Palandri F, Piciocchi A, De Stefano V, Breccia M, Finazzi G, Iurlo A et al (2020) How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy\u2014a GIMEMA MPN WP survey. Leukemia. https:\/\/doi.org\/10.1038\/s41375-020-0953-3","DOI":"10.1038\/s41375-020-0953-3"},{"key":"6601_CR29","doi-asserted-by":"publisher","first-page":"204062072311547","DOI":"10.1177\/20406207231154706","volume":"14","author":"M Marchetti","year":"2023","unstructured":"Marchetti M, Salmanton-Garcia J, El-Ashwah S, Verga L, Itri F, Racil Z et al (2023) Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry. Ther Adv Hematol 14:20406207231154706","journal-title":"Ther Adv Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06601-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06601-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06601-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:05:26Z","timestamp":1766055926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06601-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6601"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06601-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"read acknowledgements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"n\/a.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"n\/a.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"n\/a.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"Massimo Breccia is the actual Editor in Chief of Annals of Hematology and Francesca Palandri s an Associate Editor for the same journal.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}